Gilead Sciences (GILD) : Boston Private Wealth reduced its stake in Gilead Sciences by 14.95% during the most recent quarter end. The investment management company now holds a total of 269,105 shares of Gilead Sciences which is valued at $21,552,619 after selling 47,306 shares in Gilead Sciences , the firm said in a disclosure report filed with the SEC on Aug 1, 2016.Gilead Sciences makes up approximately 0.85% of Boston Private Wealth’s portfolio.
Other Hedge Funds, Including , Wright Investors Service Inc reduced its stake in GILD by selling 13,365 shares or 38.55% in the most recent quarter. The Hedge Fund company now holds 21,305 shares of GILD which is valued at $1,706,317. Gilead Sciences makes up approx 0.68% of Wright Investors Service Inc’s portfolio.Ls Investment Advisors boosted its stake in GILD in the latest quarter, The investment management firm added 2,391 additional shares and now holds a total of 138,194 shares of Gilead Sciences which is valued at $11,960,691. Gilead Sciences makes up approx 0.80% of Ls Investment Advisors’s portfolio.Tiaa Cref Trust Co Fsbmo boosted its stake in GILD in the latest quarter, The investment management firm added 10,236 additional shares and now holds a total of 146,691 shares of Gilead Sciences which is valued at $12,696,106. Gilead Sciences makes up approx 0.11% of Tiaa Cref Trust Co Fsbmo’s portfolio. Id Management As added GILD to its portfolio by purchasing 48,835 company shares during the most recent quarter which is valued at $4,245,227. Gilead Sciences makes up approx 1.29% of Id Management As’s portfolio.Gulf International Bank (uk) Ltd reduced its stake in GILD by selling 23,857 shares or 5.48% in the most recent quarter. The Hedge Fund company now holds 411,100 shares of GILD which is valued at $35,251,825. Gilead Sciences makes up approx 0.58% of Gulf International Bank (uk) Ltd’s portfolio.
Gilead Sciences closed down -0.32 points or -0.40% at $79.77 with 97,38,262 shares getting traded on Thursday. Post opening the session at $80.21, the shares hit an intraday low of $79.55 and an intraday high of $80.63 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.
Investors should note that on Jul 25, 2016, Gilead Sciences announced a cash dividend of $0.4700. The company’s management has announced Sep 14, 2016 as the ex-dividend date and fixed the record date on Sep 16, 2016. The payable date has been fixed on Sep 29, 2016.
Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Argus to ” Hold” on Jul 29, 2016. Shares were Reiterated by RBC Capital Mkts on Jul 26, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $120 .Gilead Sciences was Downgraded by Needham to ” Hold” on Jul 26, 2016.
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.